The future is looking bright for Futura Medical, with the UK R&D firm submitting earlier this month an OTC marketing approval dossier for its erectile dysfunction (ED) treatment MED3000 in the European Union and having a second pre-submission meeting with the US Food and Drug Administration under its belt.
“We are pleased to have now submitted MED3000 for European approval as a clinically proven treatment for ED,” commented Futura CEO James Barder
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?